Thanks for posting, Rossi.It's great to have everyone's input - even more so when their analysis may differ from mine.
I just don't see any value add in bringing on another Tillet or Andersson. The bases are loaded in my opinion.
You note that a large pharma would wait until we've received our results (assuming Israeli trial). These results aren't due, unless otherwise authorised, for release until the end of 2021. We've got ~40 trial results now - what's one extra?
In what I've read our position sounds almost identical to that of agios in 2010. Only, were holding decades worth of trial data.
Responsibilities of the team, page-75
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
-0.030(1.86%) |
Mkt cap ! $264.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.58 | $6.368K | 4.013K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 257 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 100 | 1 |
View Market Depth
| Last trade - 11.19am 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.57 |
Change
-0.030 ( 0.22 %) |
||||
| Open | High | Low | Volume | ||
| $1.58 | $1.58 | $1.57 | 2171 | ||
| Last updated 11.45am 16/05/2024 ? | |||||
| RAC (ASX) Chart |